ASH: How Should BCMA-Directed Bispecifics Fit Into Myeloma Treatment?

The latest data and expert opinions on BCMA-directed bispecific antibodies for multiple myeloma – including Johnson & Johnson’s Tecvayli (teclistamab-cqyv) and Pfizer’s Elrexfio (elranatamab-bcmm), which have US Food and Drug Administration approval, and Regeneron Pharmaceuticals’ linvoseltamab, which is pending at the FDA – are sparking discussions about how they will fit into the market relative to each other and relative to CAR-T cell therapies.

All three bispecifics were the subject of presentations at the American Society of Hematology annual meeting, which took place in...